EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sesen Bio's Enterprise Value is €0.00 Mil.
Sesen Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was €24.79 Mil. Therefore, Sesen Bio's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Sesen Bio's EV-to-FCF or its related term are showing as below:
STU:PCBK's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 9.77 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-24), Sesen Bio's stock price is €10.598.
Sesen Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was €-1.835. Therefore, Sesen Bio's PE Ratio for today is At Loss.
Sesen Bio EV-to-FCF Historical Data
The historical data trend for Sesen Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sesen Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sesen Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sesen Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sesen Bio's EV-to-FCF falls into.
Sesen Bio's current Enterprise Value is €0.00 Mil.
Sesen Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €24.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sesen Bio (STU:PCBK) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sesen Bio's share price for today is €10.598.
Sesen Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.835.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sesen Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Sesen Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:PCBK has been successfully added to your 